Abstract |
The present study investigated the effects of molsidomine, a predominant venous dilator which, contrary to organic nitrates, does not produce pharmacological tolerance on splanchnic and systemic hemodynamics in patients with cirrhosis. Twenty-seven cirrhotic portal hypertensive patients were studied prior to and up to 2 h after the oral administration of 2 mg of molsidomine (n = 11), 4 mg of molsidomine (n = 8) or placebo (n = 8). Molsidomine caused a significant reduction in the hepatic venous pressure gradient. The mean decrease at 60 min was -6.8 +/- 9% after 2 mg (p less than 0.05) and -15.4 +/- 12% after 4 mg (p less than 0.01). The decrease in the hepatic venous pressure gradient was maintained at 120 min: -11% after 2 mg (p less than 0.05) and -19% with 4 mg (p less than 0.01). This was associated with mild changes in azygos blood flow and with a significant decrease in hepatic blood flow (-17%, p less than 0.05). There was a moderate reduction in mean arterial pressure (-12.6% after 2 mg and -13.2% after 4 mg, p less than 0.01), which was due to a reduction in cardiac output, without any significant fall in systemic vascular resistance. Placebo administration did not change systemic or hepatic hemodynamics. This study shows that molsidomine causes a significant and sustained reduction in portal pressure in patients with cirrhosis, suggesting the potential role of this agent in the treatment of portal hypertension.
|
Authors | L Ruiz del Arbol, J C García-Pagán, F Feu, M P Pizcueta, J Bosch, J Rodés |
Journal | Journal of hepatology
(J Hepatol)
Vol. 13
Issue 2
Pg. 179-86
(Sep 1991)
ISSN: 0168-8278 [Print] Netherlands |
PMID | 1744422
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Delayed-Action Preparations
- Molsidomine
|
Topics |
- Adult
- Aged
- Delayed-Action Preparations
- Dose-Response Relationship, Drug
- Female
- Hemodynamics
(drug effects)
- Hepatic Veins
(drug effects)
- Humans
- Hypertension, Portal
(drug therapy, etiology, physiopathology)
- Liver Cirrhosis
(complications)
- Male
- Middle Aged
- Molsidomine
(pharmacology, therapeutic use)
- Splanchnic Circulation
(drug effects)
|